Get startedLog in
    Picture of Kdventures AB logo

    KDV B — Kdventures AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    FinancialsSpeculativeMicro CapSucker Stock
    All News

    Brief: Umecrine Cognition Shows Positive Interim Results in Phase 1B/2A Study

    Picture of Kdventures AB logoKdventures AB
    18/11/2024 08:56
    Nov 18 (Reuters) - Karolinska Development AB  KDEV.ST :
    * KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY UMECRINE
COGNITION
PRESENTS POSITIVE INTERIM DATA FROM PHASE 1B/2A CLINICAL STUDY
    * PRELIMINARY RESULTS: GOLEXANOLONE WELL-TOLERATED, ACHIEVED
DRUG
EXPOSURE LEVELS THAT CORRELATE TO CLINICAL TREATMENT DOSES

Source text:  ID:nGNE87VdyG 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))

    Recent news on Kdventures AB

    See all news